Patent Assignment
Reel/Frame 050735/0465
Merger
Recorded: 2019-10-16
Pages: 7
Assignor
ALCON RESEARCH, LTD.
Executed: 2019-02-28
Assignee
ALCON RESEARCH, LLC
6201 SOUTH FREEWAY, FORT WORTH, TEXAS, 76134
Covered Properties
(39)
Stabilized Pharmaceutical Sub-Micron Suspensions and Methods of Forming Same
Application:
15/493,232 →
Publication:
US US20170216228A1
Carboxylvinyl Polymer-Containing Nanoparticle Suspensions
Application:
15/284,930 →
Publication:
US US20170020818A1
Treatment for Microbe-Induced Inflammatory Responses in the Eye
Application:
13/861,603 →
Publication:
US US20130274216A1
Brinzolamide and brimonidine for treating glaucoma
Patent:
6,316,441 →
Application:
09/832,998 →
Brinzolamide and Brimonidine for Treating Ocular Conditions
Patent:
6,242,442 →
Application:
09/601,634 →
Topical Use of Kappa Opioid Agonists to Treat Otic Pain
Patent:
6,174,878 →
Application:
09/387,359 →
Treatment of Disorders of the Outer Retina
Patent:
6,509,355 →
Application:
09/807,805 →
Prostaglandin product
Patent:
6,235,781 →
Application:
09/487,936 →
Myeloperoxidase Assay of Endotoxin-Induced Inflammation
Patent:
6,022,699 →
Application:
09/304,320 →
Use of Certain Anionic Amino Acid Based Surfactants to Enhance Antimicrobial Effectiveness of Topically Administrable Pharmaceutical Compositions
Patent:
6,146,622 →
Application:
09/399,698 →
Use of Certain Fatty Acid/Amino Acid Soaps to Enhance Antimicrobial Effectiveness of Topically Administrable Pharmaceutical Compositions
Preservative System for Topically Administrable Pharmaceutical Compositions Containing a Fatty Acid/Amino Acid Soap
Patent:
6,284,749 →
Application:
09/400,134 →
Preservative System for Topically Administrable Pharmaceutical Compositions
Patent:
6,211,238 →
Application:
09/400,133 →
13-Aza Prostaglandins for the Treatment of Glaucoma and Ocular Hypertension
Patent:
6,417,228 →
Application:
09/430,513 →
Use of Neurotrophic Factor Stimulators for the Treatment of Ophthalmic Meurodegenerative Diseases
Patent:
6,906,077 →
Application:
09/856,987 →
Serotonergic 5HT2 Agonists for Treating Glaucoma
Patent:
6,664,286 →
Application:
09/787,332 →
Prostaglandin E Receptor Agonists for Treatment of Dry Eye
Patent:
6,462,080 →
Application:
09/462,719 →
Ophthalmic Compositions Containing a Synergistic Combination of Two Polymers
Self Preserved Aqueous Pharmaceutical Compositions
Pharmaceutical Compositions Having Desirable Bioavailability
Pharmaceutical Compositions Having Desirable Bioavailability
Pharmaceutical Compositions Having Desirable Bioavailability
Pharmaceutical Compositions Having Desirable Bioavailability
Punctal Plugs and Methods of Delivering Therapeutic Agents
Topical Ophthalmic Compositions Containing Tobramycin and Dexamethasone
Topical Ophthalmic Compositions Containing Tobramycin and Dexamethasone
Patent:
7,795,316 →
Application:
11/960,196 →
Self-Preserved Aqueous Pharmaceutical Compositions
Self Preserved Aqueous Pharmaceutical Compositions
Topical Ophthalmic or Otic Solution Formulations Containing Moxifloxacin Hydrocholoride and Dexamethasone Phosphate
Topical Ophthalmic or Otic Solution Formulations Containing Moxifloxacin Hydrochloride and Dexamethasone Phosphate
Pharmaceutical Suspension
Aqueous Ophthalmic Compositions Containing Anionic Therapeutic Agents
Aqueous Pharmaceutical Compositions Containing Borate-Polyol Complexes
Aqueous Pharmaceutical Compositions Containing Borate-Polyol Complexes
Carboxyvinyl Polymer-Containing Nanoparticle Suspensions
Carboxylvinyl Polymer-Containing Nanoparticle Suspensions
High Concentration Olopatadine Ophthalmic Composition
High Concentration Olopatadine Ophthalmic Composition
Topical Ophthalmic Compositions Containing Tobramycin and Dexamethasone
Related Assignments
(9)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Mar 3, 2016
From: NOVARTIS AG
To: ALCON RESEARCH LTD.
Reel/Frame 037886/0357 →
Confirmatory Deed of Assignment Effective April 8, 2019
Oct 17, 2019
From: ALCON RESEARCH, LLC
To: NOVARTIS AG
Reel/Frame 050746/0431 →
Corrective Assignment to Correct the Assignee Address. Previously Recorded at Reel: 050746 Frame: 0431. Assignor(S) Hereby Confirms the Assignment..
Oct 18, 2019
From: ALCON RESEARCH, LLC
To: NOVARTIS AG
Reel/Frame 050767/0001 →
Assignment of Assignor's Interest
Jan 20, 2023
From: NOVARTIS AG
To: HARROW IP, LLC
Reel/Frame 062442/0255 →
Security Interest
Jan 23, 2023
From: HARROW HEALTH, INC.; HARROW IP, LLC; IMPRIMISRX, LLC; HARROW EYE, LLC
To: B. RILEY COMMERCIAL CAPITAL, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 062452/0106 →
Patent Security Agreement
Mar 30, 2023
From: HARROW IP, LLC
To: OAKTREE FUND ADMINISTRATION, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 063205/0708 →
Termination and Release of Security Interest in Intellectual Property at Reel/Frame No. 62452/0106
Mar 30, 2023
From: B. RILEY COMMERCIAL CAPITAL, LLC, AS ADMINISTRATIVE AGENT
To: HARROW HEALTH, INC.; HARROW EYE, LLC; HARROW IP, LLC; IMPRIMISRX, LLC
Reel/Frame 063206/0156 →
Release of Security Interest
Sep 18, 2025
From: OAKTREE FUND ADMINISTRATION, LLC, AS ADMINISTRATIVE AGENT
To: HARROW IP, LLC
Reel/Frame 072299/0911 →
Security Interest
Sep 26, 2025
From: HARROW, INC.; HARROW IP, LLC
To: FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT
Reel/Frame 072384/0781 →